| Maury Regional Medical Group, Inc | |
|
854 W James Campbell Blvd Suite 303 Columbia TN 38401-4659 | |
| (931) 540-4255 | |
| (931) 490-4654 |
| Full Name | Maury Regional Medical Group, Inc |
|---|---|
| Speciality | Family Medicine |
| Location | 854 W James Campbell Blvd, Columbia, Tennessee |
| Authorized Official Name and Position | Nick A Swift (CFO) |
| Authorized Official Contact | 9315404255 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Maury Regional Medical Group, Inc 854 W James Campbell Blvd Suite 303 Columbia TN 38401-4659 Ph: (931) 540-4255 | Maury Regional Medical Group, Inc 854 W James Campbell Blvd Suite 303 Columbia TN 38401-4659 Ph: (931) 540-4255 |
| NPI Number | 1205886264 |
|---|---|
| Provider Enumeration Date | 05/11/2006 |
| Last Update Date | 02/20/2024 |
| Medicare PECOS PAC ID | 7911810742 |
|---|---|
| Medicare Enrollment ID | O20040227000252 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205886264 | NPI | - | NPPES |
| 3710089 | Medicaid | TN |
| Provider Name | Rosemary E Davenport |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811900095 PECOS PAC ID: 9638063829 Enrollment ID: I20040210000067 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brian R Mcmurray |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1750324315 PECOS PAC ID: 0941196000 Enrollment ID: I20040225000649 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Nathanael L Lafferty |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1750494969 PECOS PAC ID: 1456249937 Enrollment ID: I20040306000243 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | James R Hayes |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1730292913 PECOS PAC ID: 3577451053 Enrollment ID: I20040306000291 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Shawn N Gentry |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891708012 PECOS PAC ID: 9436049707 Enrollment ID: I20040318001633 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Thomas W Farmer |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1114019833 PECOS PAC ID: 4880586833 Enrollment ID: I20040325001410 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Esmeraldo D Herrera |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1174501597 PECOS PAC ID: 3779575584 Enrollment ID: I20040401000441 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Robert A Bain |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1891887659 PECOS PAC ID: 4587656111 Enrollment ID: I20040401001396 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | James C Couch |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1376635052 PECOS PAC ID: 5597757153 Enrollment ID: I20040401001588 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Dannylu J Wilson |
|---|---|
| Provider Type | Practitioner - Certified Clinical Nurse Specialist (cns) |
| Provider Identifiers | NPI Number: 1972673648 PECOS PAC ID: 4486649563 Enrollment ID: I20040417000604 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joseph Anthony Destefano |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508841032 PECOS PAC ID: 4688669526 Enrollment ID: I20040419001314 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Christina L Lannom |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1700871191 PECOS PAC ID: 0749276913 Enrollment ID: I20040422001123 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jalila Hudson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1598773889 PECOS PAC ID: 4284615337 Enrollment ID: I20040526000139 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kelly J Snyder |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487749446 PECOS PAC ID: 7214835222 Enrollment ID: I20040610001791 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Laurence T Britt |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1548245285 PECOS PAC ID: 9830173772 Enrollment ID: I20040617000136 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jacqueline R Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1326192519 PECOS PAC ID: 8325023633 Enrollment ID: I20040621001953 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jon L Freels |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1336200385 PECOS PAC ID: 7618955972 Enrollment ID: I20040712001608 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | James Marshall |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1710955034 PECOS PAC ID: 7214915412 Enrollment ID: I20040713001068 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Paula A Cole |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649202953 PECOS PAC ID: 3173503885 Enrollment ID: I20040722001355 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joe R Fite |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1346291952 PECOS PAC ID: 6002896727 Enrollment ID: I20040722001387 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Leonard Gleen Webster |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1386710762 PECOS PAC ID: 8325019177 Enrollment ID: I20040804000973 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Robbie M Webb |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043283765 PECOS PAC ID: 0749254712 Enrollment ID: I20040825000046 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Patrick A Souris |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1467506576 PECOS PAC ID: 8921077652 Enrollment ID: I20040929001020 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Gordon L Melton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619064748 PECOS PAC ID: 2365407327 Enrollment ID: I20041201000634 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Karen J Perry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659463206 PECOS PAC ID: 9537125745 Enrollment ID: I20041208000880 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jawaid Kamal |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538131073 PECOS PAC ID: 7113820739 Enrollment ID: I20041210000573 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Martin M Chaney |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891773057 PECOS PAC ID: 4486692035 Enrollment ID: I20050422000928 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Mark A Seago |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1497732762 PECOS PAC ID: 5991743544 Enrollment ID: I20050422000981 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Dayaker R Mallipeddi |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1548225444 PECOS PAC ID: 1153364898 Enrollment ID: I20050603000806 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John W Coursey |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1114998507 PECOS PAC ID: 0446289466 Enrollment ID: I20050810000747 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Denise G Werner |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1306953161 PECOS PAC ID: 1658397500 Enrollment ID: I20051019001118 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Timothy A Nash |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851407548 PECOS PAC ID: 4284650136 Enrollment ID: I20051019001121 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Julie S Wood |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255323721 PECOS PAC ID: 5597788414 Enrollment ID: I20060106000197 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Russell J Berscheid |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1386795326 PECOS PAC ID: 0749203594 Enrollment ID: I20060109000243 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Barbara N Hinson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780753509 PECOS PAC ID: 1052334216 Enrollment ID: I20060113000385 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Rodney B Gilbert |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1861478026 PECOS PAC ID: 2365465614 Enrollment ID: I20060118000112 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Bhaskar Reddy |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1285610105 PECOS PAC ID: 2567426182 Enrollment ID: I20060118000140 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Charles A Ball |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1154344836 PECOS PAC ID: 9537137401 Enrollment ID: I20060209000275 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Thomas Edward Quinn |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1386710051 PECOS PAC ID: 7719968460 Enrollment ID: I20060316000354 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John Beuerlein |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1417040205 PECOS PAC ID: 5092723395 Enrollment ID: I20060328000756 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Holly K Meeker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295778785 PECOS PAC ID: 1052320389 Enrollment ID: I20060414000086 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kendra R Prater-holt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548292840 PECOS PAC ID: 7517961501 Enrollment ID: I20060906000093 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Hrishi M Kanth |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154342046 PECOS PAC ID: 3072518877 Enrollment ID: I20060929000441 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Susana I Donaghey |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1427073451 PECOS PAC ID: 3072418953 Enrollment ID: I20061213000393 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | David M Turner |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1932188554 PECOS PAC ID: 7113021361 Enrollment ID: I20070414000120 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John G Garrett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770594079 PECOS PAC ID: 0345349890 Enrollment ID: I20070623000105 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Takasha L Stewart-hubbard |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1467423491 PECOS PAC ID: 3173418043 Enrollment ID: I20070625000755 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Patricia W Cagle |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184672446 PECOS PAC ID: 2961594528 Enrollment ID: I20070828000074 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michael J Pelletier |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1841295672 PECOS PAC ID: 5193818813 Enrollment ID: I20070911000321 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Angela M Zuill |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023233780 PECOS PAC ID: 0345334611 Enrollment ID: I20070917000687 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Loretta Davidson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295952505 PECOS PAC ID: 6608960976 Enrollment ID: I20070917000693 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | William Robert Stewart |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1821068040 PECOS PAC ID: 8426035866 Enrollment ID: I20080304000600 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Gibran B Naddy |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962470567 PECOS PAC ID: 4880783737 Enrollment ID: I20080506000042 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kelley V Jefferson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154398105 PECOS PAC ID: 9335210616 Enrollment ID: I20080613000067 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Mark A Mclean |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1265450597 PECOS PAC ID: 9638250236 Enrollment ID: I20080630000050 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Maura J Lipp |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1821257502 PECOS PAC ID: 6800969973 Enrollment ID: I20080723000220 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Reba J Mccoy |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780848226 PECOS PAC ID: 2668547589 Enrollment ID: I20080812000511 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Grace Wu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689891889 PECOS PAC ID: 3577639558 Enrollment ID: I20080828000256 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brandi L King |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1245488162 PECOS PAC ID: 7012077324 Enrollment ID: I20081117000434 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Anthony L Aird |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1457513517 PECOS PAC ID: 0446313944 Enrollment ID: I20090109000278 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Oliver Patrick Archibald |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174508105 PECOS PAC ID: 8022197169 Enrollment ID: I20090224000651 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michelle Desha Martin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1871733725 PECOS PAC ID: 5698824860 Enrollment ID: I20090518000393 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Monica Peeler |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1952507063 PECOS PAC ID: 4789735549 Enrollment ID: I20090708000196 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Dana J Chandler |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1518143122 PECOS PAC ID: 6305998303 Enrollment ID: I20090722000737 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Christopher P Turner |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1659474336 PECOS PAC ID: 0547313736 Enrollment ID: I20090805000733 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Steven C Smith |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1972708667 PECOS PAC ID: 6608929807 Enrollment ID: I20090805000760 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Srikar S Reddy |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1467418087 PECOS PAC ID: 6709861735 Enrollment ID: I20090807000174 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michael J Davidson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1740240902 PECOS PAC ID: 5698773091 Enrollment ID: I20100208000023 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michael D Brunson |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1679500102 PECOS PAC ID: 2961580006 Enrollment ID: I20100223000173 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John O Simmons |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1245208602 PECOS PAC ID: 0840276762 Enrollment ID: I20100311000115 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Shawn L Reed |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104894401 PECOS PAC ID: 0244329183 Enrollment ID: I20100318000104 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Gaylon L Harris |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1740258011 PECOS PAC ID: 5799874632 Enrollment ID: I20100318000123 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Emilio J Rodriguez-viera |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1578531851 PECOS PAC ID: 7517056450 Enrollment ID: I20100318000144 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Anuradha P Mann |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578531174 PECOS PAC ID: 1153410097 Enrollment ID: I20100318000163 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Anthony D Khim |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1295736940 PECOS PAC ID: 7113988197 Enrollment ID: I20100602000493 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Sandra Kilburn Daniel |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992947568 PECOS PAC ID: 5294866067 Enrollment ID: I20100623000872 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Carey L Barr |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720070949 PECOS PAC ID: 0648301986 Enrollment ID: I20100630000162 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Harish Veeramachineni |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1821217852 PECOS PAC ID: 0244362937 Enrollment ID: I20100715000537 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Charlotte Anne Batey |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1265433916 PECOS PAC ID: 5890827976 Enrollment ID: I20100726000475 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Tinu Emmanuel Thomas |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1740404227 PECOS PAC ID: 5496889487 Enrollment ID: I20100812000522 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kenneth D Fulks |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1144237751 PECOS PAC ID: 3971637463 Enrollment ID: I20100819000628 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kanthi Charan Narra |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982829297 PECOS PAC ID: 9638295488 Enrollment ID: I20100929000694 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Chet H Jameson |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1891788840 PECOS PAC ID: 4789877358 Enrollment ID: I20101015000505 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | James H Vernier |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1457334328 PECOS PAC ID: 8921095217 Enrollment ID: I20101029000710 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jodie M Baumtrog |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295059186 PECOS PAC ID: 4486849833 Enrollment ID: I20101110001181 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Robert Mcclure |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1386600906 PECOS PAC ID: 5890770820 Enrollment ID: I20101208000864 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Amit A Choksi |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1376508374 PECOS PAC ID: 4981689916 Enrollment ID: I20101208000890 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Ben A Gardner |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1316054133 PECOS PAC ID: 9537356001 Enrollment ID: I20101209000498 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Akberet B Hadgu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1548471501 PECOS PAC ID: 1850588369 Enrollment ID: I20101209001030 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Deborah Lynn Goldsmith |
|---|---|
| Provider Type | Practitioner - Infectious Disease |
| Provider Identifiers | NPI Number: 1710058136 PECOS PAC ID: 3476740671 Enrollment ID: I20101214001096 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kathrynne O Simmons |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346545746 PECOS PAC ID: 4385826114 Enrollment ID: I20110315000605 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Mark H Messenger |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1568455517 PECOS PAC ID: 2264615871 Enrollment ID: I20110318000786 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Justin K Kropf |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1942428628 PECOS PAC ID: 0749467306 Enrollment ID: I20110608000252 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joe Mobley |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1356597983 PECOS PAC ID: 2264626498 Enrollment ID: I20110719000399 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Christopher Edwards |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104897164 PECOS PAC ID: 1153306931 Enrollment ID: I20110823000964 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Giorgi Sirbiladze |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1407037112 PECOS PAC ID: 4587834445 Enrollment ID: I20110901000105 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Robert B Lee |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1285785709 PECOS PAC ID: 8325933385 Enrollment ID: I20110921000525 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Mark A Graves |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881977684 PECOS PAC ID: 4486827342 Enrollment ID: I20111109000623 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Daniel Davidson Oxley |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1174572796 PECOS PAC ID: 7618860065 Enrollment ID: I20111202000712 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Shelly M Hargrove |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780961987 PECOS PAC ID: 3779759568 Enrollment ID: I20111228000554 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Lindsey Shay Cunningham |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346517927 PECOS PAC ID: 3870760036 Enrollment ID: I20120111000849 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John S Jensen |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1124246681 PECOS PAC ID: 4789851346 Enrollment ID: I20120123000276 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Melissa J Raymer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1467609735 PECOS PAC ID: 4486811957 Enrollment ID: I20120210000626 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Mark A Cobb |
|---|---|
| Provider Type | Practitioner - Neurosurgery |
| Provider Identifiers | NPI Number: 1336144245 PECOS PAC ID: 3678753183 Enrollment ID: I20120229000655 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Cenchrea Lanier |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1962775999 PECOS PAC ID: 7911168448 Enrollment ID: I20120410000702 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Sarah E Fitzgerald |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164607073 PECOS PAC ID: 5890957195 Enrollment ID: I20120503000080 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Tara T Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619242187 PECOS PAC ID: 0648434621 Enrollment ID: I20120605000168 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Alisha M Williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265707350 PECOS PAC ID: 4385808641 Enrollment ID: I20120618000238 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Selorm A Adzokpa |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508002015 PECOS PAC ID: 4183880214 Enrollment ID: I20120718000296 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Candice T Olechowski |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962656322 PECOS PAC ID: 6305092727 Enrollment ID: I20120817000030 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brandie H Gorrell |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871754515 PECOS PAC ID: 8820244262 Enrollment ID: I20120817000198 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Olivia M Granillo Johnson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1437316106 PECOS PAC ID: 1456507896 Enrollment ID: I20120817000213 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Andrew T Szaflarski |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1366695363 PECOS PAC ID: 5890941447 Enrollment ID: I20120821000912 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Cyrilyn A Walters |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1487867487 PECOS PAC ID: 2264680578 Enrollment ID: I20120911000725 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Padma Narra |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902035371 PECOS PAC ID: 1355599309 Enrollment ID: I20120917000189 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Robin E Lapre |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1194741488 PECOS PAC ID: 1557510856 Enrollment ID: I20121002000214 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Lynda S Murff |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1104912013 PECOS PAC ID: 7517117930 Enrollment ID: I20121022000087 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Chassie E Harris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851636203 PECOS PAC ID: 2860646031 Enrollment ID: I20130218000199 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Evans N Mize |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1831414358 PECOS PAC ID: 6709031750 Enrollment ID: I20130225000312 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | David B Beck |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659619161 PECOS PAC ID: 2264677277 Enrollment ID: I20130322000154 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Timothy C Dickey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750621579 PECOS PAC ID: 6800032681 Enrollment ID: I20130424000190 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kendra L Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013256064 PECOS PAC ID: 7618113143 Enrollment ID: I20130429000249 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Margaret C Norris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609886142 PECOS PAC ID: 6305803990 Enrollment ID: I20130529000460 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Shavonne Morgan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720326200 PECOS PAC ID: 5294974564 Enrollment ID: I20130617000709 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jim T Harris |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1598994147 PECOS PAC ID: 8527237478 Enrollment ID: I20130618000128 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Karthik Jothianandan |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1184867939 PECOS PAC ID: 0244386571 Enrollment ID: I20130802000237 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joe Philip |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1831345669 PECOS PAC ID: 1254484892 Enrollment ID: I20130805000277 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Rodney James Snodgrass Deaton |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1003934274 PECOS PAC ID: 8921240425 Enrollment ID: I20130813000561 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Dominic J Papa |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134355647 PECOS PAC ID: 5092954313 Enrollment ID: I20130828000879 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Courtney B Clark |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376985036 PECOS PAC ID: 0345483756 Enrollment ID: I20130904000862 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Lance Micheel Freeman |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1205097565 PECOS PAC ID: 4688817869 Enrollment ID: I20130909000342 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brett Norman |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1881850667 PECOS PAC ID: 3971773847 Enrollment ID: I20130916000318 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jerald L Taggart |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1881851483 PECOS PAC ID: 6204017247 Enrollment ID: I20130917000503 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jennifer J Feldhaus |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1033353487 PECOS PAC ID: 9537305354 Enrollment ID: I20131004000382 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Wanda Williams |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1720212350 PECOS PAC ID: 1355592916 Enrollment ID: I20131009001567 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Zakaria M Botros |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1275828089 PECOS PAC ID: 2264668524 Enrollment ID: I20131115001439 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Louise A Hawkins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952744286 PECOS PAC ID: 4183851173 Enrollment ID: I20131219000747 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Ben R Barton |
|---|---|
| Provider Type | Practitioner - Thoracic Surgery |
| Provider Identifiers | NPI Number: 1487757605 PECOS PAC ID: 7517971294 Enrollment ID: I20140325000259 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Julie L Finch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629490032 PECOS PAC ID: 3577786334 Enrollment ID: I20140523000191 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Steven R Mead |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427473792 PECOS PAC ID: 1153545579 Enrollment ID: I20140604002396 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Leopoldo Mario Basilico |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1538480603 PECOS PAC ID: 7214150051 Enrollment ID: I20140821002098 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Megan R Rahmlow |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1043475288 PECOS PAC ID: 1456520345 Enrollment ID: I20140904001626 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Danielle L Henson |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1982999413 PECOS PAC ID: 4082857107 Enrollment ID: I20140922000334 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Lindsay Randle Norton |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1164748430 PECOS PAC ID: 7810117066 Enrollment ID: I20141009002627 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jeffry Ruff |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1265753339 PECOS PAC ID: 8224278320 Enrollment ID: I20141013001299 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Rebecca H Smith |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1861639031 PECOS PAC ID: 5294874764 Enrollment ID: I20141020000499 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Bradley K Rodgers |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1285950006 PECOS PAC ID: 9032432661 Enrollment ID: I20150106001361 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Nilay B Patel |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1619397957 PECOS PAC ID: 2466776760 Enrollment ID: I20150114002037 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Bradley Holmes |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043483316 PECOS PAC ID: 0648597963 Enrollment ID: I20150326000584 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jessica M Barnwell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417345521 PECOS PAC ID: 0941527071 Enrollment ID: I20150328000165 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Barry Michael Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225420490 PECOS PAC ID: 7012237654 Enrollment ID: I20150521000720 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Leslie Nowlin Mcbroom |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629465133 PECOS PAC ID: 4587985395 Enrollment ID: I20150604002957 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Amy Lynn Richardson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205221884 PECOS PAC ID: 3779895834 Enrollment ID: I20150701001832 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jessica L Oliver |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851782486 PECOS PAC ID: 0941512081 Enrollment ID: I20150702001438 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Sarah D Essary |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1578857017 PECOS PAC ID: 4981919057 Enrollment ID: I20150818006113 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joanna Christine Shepherd |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1407141302 PECOS PAC ID: 1557682499 Enrollment ID: I20150902000890 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Loraine Ogbenyealu Achebe |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1073807582 PECOS PAC ID: 6507172434 Enrollment ID: I20150908002418 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Izuchukwu Iwueke |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1568717734 PECOS PAC ID: 2567779614 Enrollment ID: I20150922001569 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kelly K Foltermann |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1407141773 PECOS PAC ID: 0648435123 Enrollment ID: I20151014003407 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Nicole Falls |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1982993572 PECOS PAC ID: 5496064164 Enrollment ID: I20151020001137 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jacob Don Kelley |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1992095376 PECOS PAC ID: 5395982193 Enrollment ID: I20151023001550 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Elijah Kim |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1003045097 PECOS PAC ID: 0840500906 Enrollment ID: I20151103000186 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michael Nottidge |
|---|---|
| Provider Type | Practitioner - Critical Care (intensivists) |
| Provider Identifiers | NPI Number: 1700922630 PECOS PAC ID: 7012059090 Enrollment ID: I20151104002129 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Griffin Andrew Guice |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1891085270 PECOS PAC ID: 7517103153 Enrollment ID: I20151112002098 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Niccole R Crowley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750750790 PECOS PAC ID: 8224348792 Enrollment ID: I20151112002491 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Lindsey Chapman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265809305 PECOS PAC ID: 1658681978 Enrollment ID: I20151117000322 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jason L Cunningham |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285004085 PECOS PAC ID: 1759681950 Enrollment ID: I20151119001372 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Thang M Phan |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1558653923 PECOS PAC ID: 8820398662 Enrollment ID: I20151130000845 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Katherine Ring |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740669191 PECOS PAC ID: 1153621503 Enrollment ID: I20151208000726 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Christopher Michael Merrick |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1942566419 PECOS PAC ID: 7719289693 Enrollment ID: I20160224000149 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Chessica L Runyon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174990105 PECOS PAC ID: 2466751367 Enrollment ID: I20160427001598 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Elizabeth F Farrell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1619335866 PECOS PAC ID: 9133428030 Enrollment ID: I20160427001745 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | William M Rasberry |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1356786669 PECOS PAC ID: 0143469817 Enrollment ID: I20160603000433 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Heather A Steele |
|---|---|
| Provider Type | Practitioner - Medical Oncology |
| Provider Identifiers | NPI Number: 1538209606 PECOS PAC ID: 3577883883 Enrollment ID: I20160707000551 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kerry Peete |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639530934 PECOS PAC ID: 8426341637 Enrollment ID: I20160726002112 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jennifer L Krauland |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1548557150 PECOS PAC ID: 1153615539 Enrollment ID: I20160808001728 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Geraldo Enrique Holguin |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1528360765 PECOS PAC ID: 9436320926 Enrollment ID: I20160816000040 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Alexis Dunlap |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588051726 PECOS PAC ID: 8628381431 Enrollment ID: I20161012000695 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Rafael Favela |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1659631299 PECOS PAC ID: 7012146665 Enrollment ID: I20161018002923 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | James Hall |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1073533956 PECOS PAC ID: 1658475843 Enrollment ID: I20161019000588 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jennifer Adams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013331941 PECOS PAC ID: 5092948752 Enrollment ID: I20161201000958 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Peter Hsu |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1003173592 PECOS PAC ID: 1557597176 Enrollment ID: I20170302000480 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Linda P Monroe |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1912006859 PECOS PAC ID: 9032007521 Enrollment ID: I20170328000403 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jennifer Green |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073064242 PECOS PAC ID: 5294012555 Enrollment ID: I20170516000177 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John M Douglas |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1730566175 PECOS PAC ID: 1557681756 Enrollment ID: I20170601000895 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kimberly Richardson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689101503 PECOS PAC ID: 6002186640 Enrollment ID: I20170714000959 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Amy E Vertrees |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1134324544 PECOS PAC ID: 0941447106 Enrollment ID: I20170802002957 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Peter Y Shi |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1336569904 PECOS PAC ID: 6901178946 Enrollment ID: I20170825000224 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Sean C Cannady |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1487067963 PECOS PAC ID: 1658673900 Enrollment ID: I20170901002626 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Gretchen R Nelson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851484000 PECOS PAC ID: 5799783452 Enrollment ID: I20170913003914 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Varun C Dhulipala |
|---|---|
| Provider Type | Practitioner - Hematology |
| Provider Identifiers | NPI Number: 1902196165 PECOS PAC ID: 1254578800 Enrollment ID: I20170922001174 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John C Welker |
|---|---|
| Provider Type | Practitioner - Pain Management |
| Provider Identifiers | NPI Number: 1346477221 PECOS PAC ID: 9638478787 Enrollment ID: I20170923000457 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Phillip A Rodriguez |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1043658867 PECOS PAC ID: 3375832017 Enrollment ID: I20171002000905 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jonathan Dale Casey |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1780904631 PECOS PAC ID: 8123266624 Enrollment ID: I20171004003143 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Stephen Halliday |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1154612554 PECOS PAC ID: 0941502785 Enrollment ID: I20171006000895 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Ryan Milo Brown |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1164865507 PECOS PAC ID: 6608170576 Enrollment ID: I20171016000773 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Andrius Lescauskas |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1316351844 PECOS PAC ID: 8224304472 Enrollment ID: I20171016003364 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Patrick T Davis |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1003101684 PECOS PAC ID: 3577839117 Enrollment ID: I20171025003026 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Emily Turner |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1790120541 PECOS PAC ID: 5597994137 Enrollment ID: I20171201001446 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Romany Anne Nilanthi Johnpulle |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1962632968 PECOS PAC ID: 0941466288 Enrollment ID: I20171214000393 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Deanna R White |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063521292 PECOS PAC ID: 9234122623 Enrollment ID: I20180504002248 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brenda M May |
|---|---|
| Provider Type | Practitioner - Gynecological Oncology |
| Provider Identifiers | NPI Number: 1265610380 PECOS PAC ID: 8022295351 Enrollment ID: I20180514002776 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Manisha Raj |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1023452331 PECOS PAC ID: 4385947993 Enrollment ID: I20180521001763 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Billy Dean Bailey |
|---|---|
| Provider Type | Practitioner - Rheumatology |
| Provider Identifiers | NPI Number: 1396730552 PECOS PAC ID: 0840327862 Enrollment ID: I20180525002204 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Taylor M Davis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497270474 PECOS PAC ID: 8628333192 Enrollment ID: I20180604002171 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Anthony D Haase |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043400435 PECOS PAC ID: 5799963401 Enrollment ID: I20180609000144 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Laurie E Bates |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477067429 PECOS PAC ID: 0547516338 Enrollment ID: I20180710000648 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jennifer Puentes Concepcion |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1841705241 PECOS PAC ID: 4880941749 Enrollment ID: I20180724000573 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joseph Anthony Veys |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1861464208 PECOS PAC ID: 8628053618 Enrollment ID: I20180807001306 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Fauzi N Rizvi |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1699734269 PECOS PAC ID: 6709848450 Enrollment ID: I20180807002761 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Matthew R Endara |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1033370937 PECOS PAC ID: 2668696733 Enrollment ID: I20180815001815 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Christian W Petrauskis |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1407274251 PECOS PAC ID: 3678822061 Enrollment ID: I20180817001902 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Raymond J Howard |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1295199719 PECOS PAC ID: 2466751912 Enrollment ID: I20180821001972 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brandon Cody Banks |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1326485426 PECOS PAC ID: 9335383033 Enrollment ID: I20180831002005 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Rebecca P Haase |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174948210 PECOS PAC ID: 8729211461 Enrollment ID: I20180919003154 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kirstin A Agent |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154808574 PECOS PAC ID: 6305197740 Enrollment ID: I20180924001580 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | David Glenn Ransom |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1144616996 PECOS PAC ID: 9436460466 Enrollment ID: I20180925002555 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Micheal Shane Blocker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487134052 PECOS PAC ID: 5698026862 Enrollment ID: I20180927000716 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Thu M Nguyen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1457746331 PECOS PAC ID: 1153615844 Enrollment ID: I20181002003844 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Katelin Thompson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194202614 PECOS PAC ID: 2062765407 Enrollment ID: I20181031002984 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Andrew K Nielsen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1093155913 PECOS PAC ID: 1254650146 Enrollment ID: I20181115001161 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Amy N Harris |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396256160 PECOS PAC ID: 8820334584 Enrollment ID: I20190116004154 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michael Gregory Lester |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255750501 PECOS PAC ID: 7911209721 Enrollment ID: I20190724000627 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Karen E Jackson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1871989483 PECOS PAC ID: 7214239813 Enrollment ID: I20190729002956 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brittany M Legg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386116697 PECOS PAC ID: 8729314604 Enrollment ID: I20190730004009 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Brandon M Gentry |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1730575689 PECOS PAC ID: 0244566131 Enrollment ID: I20190731000018 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John R Roberts |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1740635440 PECOS PAC ID: 0042500761 Enrollment ID: I20190807002788 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Luke E Habegger |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1649699893 PECOS PAC ID: 2860794880 Enrollment ID: I20190808004193 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Courtney B Hollis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518522309 PECOS PAC ID: 7214264373 Enrollment ID: I20190812003588 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Megan L Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811554884 PECOS PAC ID: 8022345024 Enrollment ID: I20190814001686 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Nicole M Grinnell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154985018 PECOS PAC ID: 2668700691 Enrollment ID: I20190828002959 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Octavia L Graham |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134581549 PECOS PAC ID: 9830441658 Enrollment ID: I20190920002904 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Shawn L Price |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1962899575 PECOS PAC ID: 7719295138 Enrollment ID: I20190925002310 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Megan Lorraine Wilson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1538721501 PECOS PAC ID: 1254663420 Enrollment ID: I20191022001068 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Lucas Wilmore |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1215399092 PECOS PAC ID: 7810286192 Enrollment ID: I20191106000443 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Robert E Bilbao |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1568817286 PECOS PAC ID: 1850689563 Enrollment ID: I20191114002641 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Shakevia V Johnson |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1104236850 PECOS PAC ID: 5092008052 Enrollment ID: I20191115001310 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Martin Lawrence Serene |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952947244 PECOS PAC ID: 1456787837 Enrollment ID: I20200203001381 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jordan Kenneth Orr |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1720499650 PECOS PAC ID: 1153615216 Enrollment ID: I20200313002101 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Edward Tang Qian |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1124472774 PECOS PAC ID: 3870886310 Enrollment ID: I20200609002734 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joshua Porter Smith |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1669719258 PECOS PAC ID: 2769600121 Enrollment ID: I20200713003753 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Dustin H Minix |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1548701220 PECOS PAC ID: 0244509388 Enrollment ID: I20200722002207 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Amanda Glynn Goethals |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255872933 PECOS PAC ID: 6002185139 Enrollment ID: I20200820003415 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michael R Hallenbeck |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1275989725 PECOS PAC ID: 0446545248 Enrollment ID: I20200824003376 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Doreen Biribwa Arinaitwe |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1851743819 PECOS PAC ID: 8729371620 Enrollment ID: I20200917000238 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Nicholas A Coman |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1205287760 PECOS PAC ID: 8325466592 Enrollment ID: I20200921001525 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Pinky R Chugani |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1972957405 PECOS PAC ID: 9739476904 Enrollment ID: I20200929002424 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Vanessa M Henri |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1659734606 PECOS PAC ID: 6002235645 Enrollment ID: I20200930002410 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Carly Cooke |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831705953 PECOS PAC ID: 4688084213 Enrollment ID: I20201110000701 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Mary Ebueku-smith |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1639514805 PECOS PAC ID: 8426329897 Enrollment ID: I20210303003100 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Samuel Welch |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427631944 PECOS PAC ID: 5294135166 Enrollment ID: I20210615000120 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Peter J Edmonds |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1417301334 PECOS PAC ID: 8426341850 Enrollment ID: I20210708001503 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Abraham Scott Mccall |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1295264026 PECOS PAC ID: 2769885342 Enrollment ID: I20210720001253 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Bushra Z Osmani |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1760746127 PECOS PAC ID: 6406079151 Enrollment ID: I20210826000272 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Liane P Gozmao |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1801317953 PECOS PAC ID: 6507263480 Enrollment ID: I20210920001559 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Benjamin J Newcomb |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1295229276 PECOS PAC ID: 6608201546 Enrollment ID: I20211117000857 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Mayonne Renner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477926517 PECOS PAC ID: 1850694514 Enrollment ID: I20220103002049 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John Patrick Selph |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1336383934 PECOS PAC ID: 9537382726 Enrollment ID: I20220218000421 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Jill Mcdonald |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528712841 PECOS PAC ID: 2062807753 Enrollment ID: I20220316000316 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Bailee M Horton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659022366 PECOS PAC ID: 6709263080 Enrollment ID: I20220509000468 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Carolyn N Lowery |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1679211650 PECOS PAC ID: 9133500671 Enrollment ID: I20220715000149 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Ruchika Talwar |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1003349440 PECOS PAC ID: 9234511775 Enrollment ID: I20220801001456 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Troy Larson |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1023542610 PECOS PAC ID: 4082987581 Enrollment ID: I20220808001277 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Frances M Hardin |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1417477266 PECOS PAC ID: 9032489653 Enrollment ID: I20220825001783 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Michael A Kreis |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1881257343 PECOS PAC ID: 5597153353 Enrollment ID: I20220825002195 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Blake E Funke |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1497281992 PECOS PAC ID: 3476824509 Enrollment ID: I20220825003482 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Elizabeth M Rodriguez |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1700447521 PECOS PAC ID: 8325373558 Enrollment ID: I20220826000288 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Joshua Ryan Bates |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922598325 PECOS PAC ID: 3274880828 Enrollment ID: I20220928000135 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Reena Baharani |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1659631950 PECOS PAC ID: 5395018865 Enrollment ID: I20221115003607 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Zachery T Sensing |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1346804176 PECOS PAC ID: 5193059699 Enrollment ID: I20230124002494 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Daniel Regan Scheurich |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1659396539 PECOS PAC ID: 7810082724 Enrollment ID: I20230209001649 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Esteban Miller |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1346236478 PECOS PAC ID: 6709074529 Enrollment ID: I20230410000469 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Htet Htet Kyaw |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1669932638 PECOS PAC ID: 0143695759 Enrollment ID: I20230413001132 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Abhish Koirala |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1134474471 PECOS PAC ID: 6507186913 Enrollment ID: I20230609000405 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Ashley N Perez |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1215216031 PECOS PAC ID: 2769653005 Enrollment ID: I20230616000177 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Matthew T. Stier |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1407410137 PECOS PAC ID: 5597094268 Enrollment ID: I20230821001973 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Rebecca Hughes |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457041006 PECOS PAC ID: 2769845049 Enrollment ID: I20230905001229 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Braden V Schuster |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1023515897 PECOS PAC ID: 4789939232 Enrollment ID: I20230908000043 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Chaohua Yan |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1417191115 PECOS PAC ID: 9638223209 Enrollment ID: I20230914000364 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | John C. Forstall |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1326571720 PECOS PAC ID: 5294009015 Enrollment ID: I20230927002179 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Taylor K Masters |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1720549744 PECOS PAC ID: 3274966866 Enrollment ID: I20231010001159 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Kathleen Anne Hiltz |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1861057275 PECOS PAC ID: 9931529419 Enrollment ID: I20231027000862 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Zalika T Nisbeth |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1902256027 PECOS PAC ID: 9436438280 Enrollment ID: I20231214000499 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Robert T Campbell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780325787 PECOS PAC ID: 3173972114 Enrollment ID: I20231215000785 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Sydney E Osborne |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568233419 PECOS PAC ID: 0446694087 Enrollment ID: I20240222000266 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
| Provider Name | Shilpa Salpekar |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528685492 PECOS PAC ID: 2466875737 Enrollment ID: I20240307001629 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
Vaccines for measles were not associated with an increased risk of febrile seizures among 4-6 year olds during the six weeks after vaccination, according to a study by the Kaiser Permanente Vaccine Study Center that appears in the current issue of Pediatrics.
Superobese gastric bypass patients appear to have improvements in quality of life and obesity-related co-existing conditions, and despite losing weight remain obese after surgery, according to a report in the April issue of Archives of Surgery.
ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
The Orlando Sentinel: Although regional plans to wire doctors' offices have circulated for some time, "this promises to be the year doctors go digital, allowing them to share patients' medical histories or pull up diagnostic test results with the click of a mouse. Health care experts predict it will be one of the biggest health care developments of 2010." Stimulus grants and incentives to get doctors and hospitals to go digital may push the earlier plans and pilot projects to fruition (Quintero, 1/8).
› Verified 1 days ago
Columbia Pediatrics Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1222 Trotwood Ave, Ste 101, Columbia, TN 38401 Phone: 931-388-8965 Fax: 931-388-0815 | |
Ybs Health And Wellness Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1040 N James Campbell Blvd Suite 114, Columbia, TN 38401 Phone: 662-212-4386 | |
Core Physicians Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1114 W 7th St, Columbia, TN 38401 Phone: 931-388-9706 Fax: 931-490-1062 | |
Stat Wellness Center, Pllc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1225 Hampshire Pike, Columbia, TN 38401 Phone: 931-982-6333 | |
Agape Family Health, Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 915 S Garden St, Columbia, TN 38401 Phone: 931-548-8090 Fax: 931-548-8110 | |
Prohealth Rural Health Services, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 180 Bear Creek Pike, Columbia, TN 38401 Phone: 931-381-7567 Fax: 931-374-9958 | |
Joe R Fite Md Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1218 Trotwood Ave, Columbia, TN 38401 Phone: 931-490-7440 Fax: 931-540-4143 |